FDA DISCLOSURE OF SAFETY AND EFFECTIVENESS DATA: A LEGAL AND POLICY ANALYSIS

A matter of great dispute between the pharmaceutical industry and the Food and Drug Administration (FDA) is the agency's public information policy. In response to the requirements of the Freedom of Information Act (FOIA), the FDA in 1974 published extensive regulations outlining which material in its files would be subject to public disclosure. Those regulations greatly changed the agency’s disclosure policy. Before they were issued, the FDA granted only about ten percent of the FOIA requests it received; after they became effective over ninety-eight percent of such requests were approved. Undoubtedly, a large percentage of the increase in successful requests was due to the clarity and detail of the regulations. Nevertheless, the new procedure signified a major change by the FDA which it labeled a “new policy of open disclosure.”

One major area affected by the regulations is the treatment of safety and effectiveness test data that must be submitted with a new

THE FOLLOWING CITATIONS WILL BE USED IN THIS COMMENT:


Pracon Incorporated, Study to Assess Impact of Releasing Safety and Effectiveness Data on the Pharmaceutical Industry’s Incentives to Invest in and Conduct Research and Development Programs (Jan. 1978) (unpublished study submitted to Office of Planning and Evaluation, Food and Drug Administration) [hereinafter cited as Pracon Study];


drug application (NDA). The FDA recognizes the proprietary interest of the submitting firm in the data, and the regulations provide that such information is not subject to release. But, because of the need to inform the public of the basis for the FDA’s approval of a particular NDA, the regulations permit the release of summaries of the data after the granting of an NDA.

This disposition of the question of confidentiality of safety and effectiveness data has not ended the debate. The FDA has professed a desire to release all safety and effectiveness data in NDAs, rather than mere summaries, but insists that such disclosure is prohibited by the trade secrets provisions of the federal criminal code and the Food, Drug and Cosmetic Act. Industry, on the other hand, would restrict access to the data in an effort to protect the return on its investment in research and development. As a result of the ongoing debate and because of the feeling that such a substantive matter should be resolved by the legislative branch, the status of safety and effectiveness data has become a major concern of the proposed Drug Regulation Reform Act.

This Comment will address both the legal and policy issues in the debate. It will be seen that the FDA’s conclusion that it lacks the authority to release the safety and effectiveness data without new legislation is uncertain. This is not to say, however, that full disclosure of this data would be sound on policy grounds. In fact, the disclosure rules included in the proposed legislation are undesirable because of the likelihood of detrimental effects on research and development and the problem of drug lag. The Comment will propose an alternative scheme of disclosure policy that should accomplish the goals of full disclosure—opening up FDA decision making and reducing expensive duplicative testing—without the costs inherent in complete release of the data.

7. 39 Fed. Reg. 44,602, 44,612 (1974). The preamble to the regulations states that the agency “agrees that there is a property right” in trade secrets and that the nondisclosure provisions of the regulations adequately reflect that right.
8. Id.
9. 21 C.F.R. § 314.14(e)(2) (1978). If the existence of the NDA had been publicly acknowledged by the submitter, the agency could release summaries of selected portions prior to a final decision by the FDA on whether to allow marketing of the drug. Id. § 314.14(d) (1978).
I. OVERVIEW OF THE LICENSING PROCEDURE FOR NEW DRUGS

Safety and effectiveness data form an essential part of the drug licensing procedure. The 1962 amendments to the Food, Drug and Cosmetic Act provide that no new drug can be marketed in the absence of proof to the FDA, through test data, that the substance is both safe and effective for its intended uses. The level of proof required by the statute is "substantial evidence," which is defined as "evidence consisting of adequate and well-controlled investigations on the basis of which it could fairly and responsibly be concluded . . . that the drug will have the effect it purports or is represented to have under the conditions of use prescribed."

This evidence is not quickly or easily developed. The process of new drug development typically begins with the screening of several chemical compounds in laboratory animals for therapeutic benefits. At this point, the experimenting firm selects the most promising compounds and tests various dosage levels. If the new drug is patentable (the degree of novelty that triggers the necessity for an NDA is lower than that required to establish a patent), patent applications for the most promising and related compounds are usually filed at this stage.

Early patenting benefits all researching firms by providing notice of competitors' efforts and allowing for the avoidance of much wasteful, duplicative testing, thereby encouraging efficient allocation of the

16. Id. § 355(a).
17. Id. § 355(d).
(1) Any drug . . . the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling thereof. . . .
(2) Any drug . . . the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

The key in determining the need for an NDA, therefore, is whether the compound is generally recognized as safe and effective under the proposed conditions; not, as it is for the purpose of a patent, whether the compound is novel. J. MASHAW & R. MERRILL, INTRODUCTION TO THE AMERICAN PUBLIC LAW SYSTEM CASES AND MATERIALS 463 (1975). The patent requirement of "non-obviousness" makes specific dosage forms, compounds discussed in published scientific literature and those found in nature not patentable. INTERIM REPORT 30.
limited resources available for drug research. Although there are no statistics on the percentage of recently granted or pending NDAs that are patented, the FDA has indicated that the percentage is quite high. Between 1962 and 1975 only 29.7% of all new drug sales were of non-patented drugs. Some of those sales undoubtedly consisted of patented drugs whose patent had expired. Thus, it seems fair to conclude that the great majority of new drugs, and certainly the most important, are patented.

Before human testing of a new drug can begin, the developer must file with the FDA a “Notice of Claimed Investigational Exemption for a New Drug” (IND). In this document the developer must disclose the composition of the new drug, its manufacturing formula, the results of all animal tests relating to the drug’s therapeutic promise and a detailed description of the proposed human testing (the protocol). If the FDA does not contest the IND within 30 days, it becomes effective and human testing can begin.

The testing of experimental drugs on human subjects is carried out in three stages. In Phase I the drug is given to a small number of voluntary healthy subjects, usually less than ten, to determine whether the drug is reasonably safe for human use and to ascertain the appropriate dosage level and form. After this is completed, the human testing enters Phase II, which consists of trials on a larger, but still very limited, population aimed at determining the effectiveness of the drug. If these results are satisfactory, the drug will enter the final and most extensive stage of testing. Phase III consists of large-scale, carefully controlled clinical trials. Hundreds of patients are usually involved in this final effort to assess the safety, effectiveness and preferred dosage of the new drug.

When all of the testing has been completed, the developer submits the test data to the FDA. This information, combined with that in the IND, is the NDA, which often consists of thousands of pages. The FDA is required by statute to act on an NDA within 180 days. In practice, however, this rarely occurs. In most cases, the agency and

21. INTERIM REPORT 30 n.98.
22. Dworkin 6. The term “new drugs” is defined as all single chemical entities, synthesized drugs, salts and esters introduced in the United States for the first time in the period under study, 1962-1975. Id.
23. 21 C.F.R. § 312 (1978); Pines, supra note 18, at 12.
25. FINAL REPORT, supra note 18, at 20; Pines, supra note 18, at 12-14.
firm either agree to an extension of time (as permitted by statute\textsuperscript{27}), or the FDA declares the NDA incomplete and seeks additional information.\textsuperscript{28}

II. Present Treatment of Safety and Effectiveness Data

The FDA's disclosure policy regarding safety and effectiveness data has undergone great evolution. Prior to the enactment of the Freedom of Information Act,\textsuperscript{29} the agency viewed all data in an NDA as strictly confidential.\textsuperscript{30} It was not until 1972, six years after the enactment of the FOIA heralded the new era of open disclosure, that the FDA attempted in proposed regulations to delineate what constituted a trade secret in an effort to clarify that exemption from the disclosure requirements of the FOIA.\textsuperscript{31} The agency acted under these proposals for two years, until the extensive "Public Information Regulations" were issued in 1974.\textsuperscript{32}

These regulations purport to release all of the safety and effectiveness data that the law permits.\textsuperscript{33} A distinction is drawn between antibiotics and other human drugs. Since petitions to market antibiotics result in publicly printed regulations rather than private licenses,\textsuperscript{34} the

\begin{itemize}
\item\textsuperscript{27} Id.
\item\textsuperscript{28} Pines, supra note 18, at 14.
\item\textsuperscript{29} 5 U.S.C. § 552 (1976).
\item\textsuperscript{30} \textit{Interim Report} 8.
\item\textsuperscript{31} 37 Fed. Reg. 9128 (1972).
\item One sarcastic reviewer of FDA policy wrote:
\begin{quote}
The regulations, like the Savior, arrived in final form on Christmas Eve, when a new babe of some 15 pages was born—preambled by 307 numbered paragraphs covering 40 pages, all swaddled in the Federal Register.

The new child, first proposed in May of 1972, was nurtured by almost 700 comment letters sent to its father—the FDA, or PBH, or both—and gestated for 2 1/2 years in the womb in Rockville.

While its final coming has been recent, the preamble informs us that the regulations have been working miracles for over two years. And, indeed, the preamble provided 60 days for further comment on new matters and promised consideration of such comments and possible changes yet to come. So, while the regulations are now final, they are not quite final. But they are probably final enough. That is, unless you want to accept the cordial invitation of the Commissioner to "institute legal action in the courts to contest their validity" and, if successful, have them declared an abortion.

O'Keefe, supra note 3, at 313.
\end{quote}
\item\textsuperscript{33} See 39 Fed. Reg. 44,602, 44,635 (1974).
\item The Commissioner agrees that public policy supports release of all safety and effectiveness data, but points out that present statutory law, 18 U.S.C. [§] 1905 and 21 U.S.C. [§] 331(f), prohibits such release . . . . The Commissioner has no authority to institute such a system [of release] without statutory authorization from Congress.
\item Id.
\item\textsuperscript{34} 21 U.S.C. § 357 (1976); 21 C.F.R. § 431 (1978).
\end{itemize}
FDA concluded that safety and effectiveness data relating to antibiotics could not be considered a trade secret or confidential commercial information\(^{35}\) and is thus subject to release. Developers of new antibiotics must therefore rely on patents to protect their research investment.

For all other new drugs intended for human use, permission to market is given in the form of a private license. In view of the large investment necessary to obtain such a license and the possibility of competitive harm to the submitting firm resulting from the release of safety and effectiveness data,\(^{36}\) the agency determined that such information was entitled to protection. But that protection is not absolute. If the applicant has made the information public,\(^{37}\) or if the drug has been disapproved, withdrawn from the market, found not to be "new," or the application abandoned, the safety and effectiveness data is subject to release “unless extraordinary circumstances are shown.”\(^{38}\)

Thus, safety and effectiveness data for approved and pending NDAs is protected unless disclosed by the developer. However, the FDA does recognize the public’s need for information regarding the basis of the agency’s decision to allow marketing of a new drug. The agency therefore releases summaries of the safety and effectiveness data following approval of an NDA.\(^{39}\) For drugs approved after July 1, 1975, the summary may be compiled by the submitter or the agency. The summary need not include the protocol for the study if it is distinguishable from other protocols and if its unique design gives the submitter a competitive advantage over other firms that are unaware of the

---

35. 21 C.F.R. § 431.71(e)(1) (1978); 39 Fed. Reg. 44,631-32 (1974). This reasoning is rejected by one commentator who presumably feels that even the antibiotic test data can be misappropriated to the competitive detriment of the developing company. Whyte, Drug Company Concerns and Opportunities—How We Will Cope, 30 FOOD, DRUG & COSM. L.J. 338, 340 (1975).

36. Even if the drug is protected by a U.S. patent, a competitor could use the data to market the drug in foreign countries where the original developer does not have a patent. In some countries, drugs are not patentable. The United States accounts for only about 18% of all world drug sales, and this market share is declining. Therefore, release of safety and effectiveness data could result in significant competitive harm to investment in research and development of the new drug, regardless of whether the drug is protected by a U.S. patent. See Dworkin Attachment B, at 2.

37. Id. § 314.14(f); see INTERIM REPORT 13-14. The preamble to the 1974 regulations offers two examples of such “extraordinary circumstances.” If a company is already marketing a drug overseas and seeks an IND for marketing in this country, but the company later has that IND terminated, the summary of data in the terminated IND could contain information that would injure the submitter’s position in the preexisting foreign market if made available to competitors. If the company could show the likelihood of such damage in “concrete terms,” the agency might invoke the “extraordinary circumstances” exemption. Another situation where the agency might not release otherwise disclosable summaries would be when such a release would directly harm the competitive status of another, pending IND or NDA. 39 Fed. Reg. 44,602, 44,633, 44,638 (1974).

particular test procedures.\textsuperscript{40}

It should be noted that even without new legislation, the FDA's public information policy has continued to evolve. In the past, the FDA has treated the very existence of an IND\textsuperscript{41} or an NDA\textsuperscript{42} as a trade secret not subject to disclosure on the theory that the applicant has a competitive interest in the maintenance of secrecy with respect to the direction of new drug research. The FDA has recently proposed changes in the disclosure regulations to permit the agency to reveal the existence, but not the content, of the notices and applications. This change, it feels, will provide "the public greater information about the agency's workload and progress in reviewing those applications."\textsuperscript{43}

Neither the present nor the proposed agency regulations, however, allow release of safety and effectiveness data, even in summary form, \textit{before} the FDA has acted on a pending NDA, with the exception of those instances where the submitter has already made the information public. Consequently, in most cases, the public is effectively precluded from offering any input whatsoever into the agency's decision regarding whether to allow marketing of a new drug.

\section*{III. Can the FDA Release the Data Under Present Law?}

In evaluating the FDA's contention that it is legally prohibited from releasing safety and effectiveness data (beyond the summaries for approved drugs), it will be helpful to pose a scenario in which the FDA favors release and then examine the theories under which a drug developer might attempt to prevent such action. The best way for the agency to establish a procedure for the release of the data would be through the promulgation of appropriate regulations under both the FOIA and 5 U.S.C. \S 301.\textsuperscript{44} The latter statute, a general housekeeping provision, gives the head of each executive department the authority to promulgate regulations for "the custody, use, and preservation of its records, papers, and property . . . [but] does not authorize withholding information from the public or limiting the availability of records to the

\begin{itemize}
\item \textsuperscript{40} 21 C.F.R. \S\S 20.61, 314.14(e)(2) (1978). This, of course, allows a company to protect its investment in new research techniques as well as the chemical entities themselves.
\item \textsuperscript{41} Id. \S 312.5.
\item \textsuperscript{42} Id. \S 314.14(b).
\item \textsuperscript{43} 43 Fed. Reg. 12,869, 12,870 (1978). The real value of this new procedure is that, like the patent system, it will identify for the public and the company's competitors the areas in which research is being conducted. This is one of the major criticisms of the present policy, and the problem is addressed in the proposed legislation. See text accompanying notes 189-98 infra.
\item \textsuperscript{44} Section 301 was originally enacted in the Act of Sept. 6, 1966, Pub. L. No. 89-554, \S 301, 80 Stat. 378.
\end{itemize}
By basing the regulations on both statutes, the FDA would protect itself from the argument that the FOIA cannot be relied upon for authorization of the release of information that falls within its exemptions.\(^4\) By its specific language, the FOIA "does not apply to matters" that fall within its nine exemptions.\(^5\) Thus, it might be argued that because safety and effectiveness data fall within the trade secrets exemption and the FOIA does not apply to that material, regulations authorizing its release cannot be based on the FOIA. This position has been taken by several courts.\(^4\) For this reason, regulations authorizing the release of material falling within the exemptions should not be based on the FOIA alone.

Section 301 provides an additional statutory basis for the regulations. The legislative history\(^4\) shows that section 301 does not permit the promulgation of regulations providing for the release of information if that release is prohibited by another statute.\(^5\) But the FOIA is not such a statute. Its exemptions are discretionary rather than mandatory.\(^5\) The Supreme Court has stated that the exemptions reflect "congressional determination of the types of information that the Executive Branch must have the option to keep confidential, if it so chooses."\(^5\) There is abundant support for this position in the legislative history of the Act. One Senate report, for example, states that "[the exemptions] are only permissive. They merely mark the outer limits of information that may be withheld when the agency makes a specific affirmative determination that the public interest and the specific circumstances dictate . . . that the information should be withheld."\(^5\)

\(^4\) 5 U.S.C § 301 (1976).
\(^5\) The submitters will claim that since the information falls within exemption 4 (the "trade secrets" exemption) of the FOIA, the FDA either cannot or should not release it. See note 76 infra and text accompanying notes 76-110 infra.
\(^7\) See NLRB v. Sears, Roebuck & Co., 421 U.S. 132, 147-48 (1975) ("if the memoranda do fall within one of the Act's exempt categories, our inquiry is at an end, for the Act 'does not apply' to such documents"); Charles River Park "A", Inc. v. Department of HUD, 519 F.2d 935, 942 (D.C. Cir. 1975); Parkridge Hosp., Inc. v. Blue Cross & Blue Shield, 430 F. Supp. 1093, 1097 (E.D. Tenn. 1977). One commentator has criticized this approach on the theory that such a restriction on FOIA regulations converts the permissive exemptions into mandatory ones. Clement 620.
\(^8\) See text accompanying notes 152-57 infra.
\(^12\) S. Rep. No. 854, 93d Cong., 2d Sess. 6 (1974) (emphasis in original); see H.R. Rep. No. 876, 93d Cong., 2d Sess. 4 (1974); Clement 598-603. Although these congressional reports as well
A. Reverse FOIA Suit—Subject Matter Jurisdiction and the Standard of Review.

If the FDA were to issue regulations authorizing the disclosure of safety and effectiveness data, the submitters of that data would likely seek injunctive relief in federal court through a "reverse FOIA suit."\(^{54}\) For years there was disagreement about the proper mode of subject matter jurisdiction in such cases. Although some courts have based jurisdiction on the FOIA itself,\(^ {55}\) most have held that the Act "is a disclosure statute and does not by its explicit terms confer jurisdiction over an action seeking to prevent disclosure."\(^ {56}\) Another conceivable source of jurisdiction is the Trade Secrets Act,\(^ {57}\) a criminal statute. While some courts have avoided this issue,\(^ {58}\) most agree that since the criminal penalties in the statute appear adequate,\(^ {59}\) no civil cause of action lies.\(^ {60}\) Another possible avenue to jurisdiction—the Administrative

---


\(^{56}\) In Planning Research Corp. v. FPC, 555 F.2d 970 (D.C. Cir. 1977), the court wrote "we express no opinion on whether § 1905 [the Trade Secrets Act] may constitute an independent basis of jurisdiction for at least some 'reverse-FOIA' suits." \(\text{Id.} \) at 977 n.12; see Charles River Park "A", Inc. v. Department of HUD, 519 F.2d 935, 941 (D.C. Cir. 1975).


\(^{59}\) This statute provides for a fine of up to $1000, or imprisonment for up to one year, or both, and automatic removal from office for any government employee who violates it.

\(^{60}\) The court in Chrysler Corp. v. Schlesinger, 565 F.2d 1172 (3d Cir. 1977), vacated and remanded sub nom. Chrysler Corp. v. Brown, 99 S. Ct. 1705 (1979), wrote:

[We] . . . reject the proposition that § 1905 [the Trade Secrets Act] . . . serve[s] as a predicate for a private civil cause of action. Recent pronouncements of the Supreme Court have severely limited the circumstances in which a federal court may imply a private cause of action from a federal statute . . . . The adequacy of these penalties would seem to assure the achievement of the Congressional objectives underlying § 1905.

565 F.2d at 1188 (footnotes omitted); the Supreme Court agreed with this analysis, 99 S. Ct. at 1725. See Sears, Roebuck & Co. v. Eckerd, 575 F.2d 1197 (7th Cir. 1978); General Dynamics Corp. v. Marshall, 572 F.2d 1211 (8th Cir. 1978), vacated and remanded, 99 S. Ct. 2024 (1979). But
Procedure Act (APA)—was blocked by the Supreme Court when it ruled in *Califano v. Sanders* that section 10 of the APA does not grant subject matter jurisdiction independent of other grounds.

Since *Sanders*, there has been general agreement that reverse-FOIA suits may be heard under general federal question jurisdiction. Because such actions are designed to prevent disclosure by a federal agency or officer, there is no requirement of a $10,000 amount in controversy.

Some courts, recognizing the policy behind these exemptions, have argued that the FOIA poses a federal question within the court’s equitable jurisdiction. Other courts have ruled more generally that “federal question jurisdiction may be sustained whether the action is viewed as ‘arising under’ [the] FOIA itself or whether it is conceived more broadly as the assertion of a private party’s right ‘to be free from agency action which adversely affects him and is not authorized by federal law.’” Thus, it is clear that the submitters will not find subject matter jurisdiction an obstacle to having a court hear their challenge to the FDA disclosure regulations.

Next, the court must determine the proper standard of review. This is a two-step process. If the FDA were to contest whether safety and effectiveness data falls within the trade secrets exemption of the FOIA, then the court would be required to conduct a full review on this issue. It is unlikely, however, that the agency would dispute this point. Rather, it would argue that although the data does fall within an exemption, the agency has discretionary authority to disclose such information and the decision to release can be set aside only if it is found to constitute an abuse of discretion. This position, adopting the stan-

---


65. See text accompanying notes 52-53 supra.


standard of the APA,\textsuperscript{69} has been accepted by a majority of the courts.\textsuperscript{70}

There is some authority for the proposition that if the submitter of information were to bring suit for a declaratory judgment prior to any release of data by the agency, then the standard of review would not be limited to the APA "abuse of discretion" test.\textsuperscript{71} Since the agency has not acted, it is argued, there is no act to which agency discretion can be applied. This argument ignores the limitations of declaratory judgment procedure: it "will not be used to pre-empt and prejudge issues that are committed for initial decision to an administrative body or special tribunal any more than it will be used as a substitute for statutory methods of review."\textsuperscript{72} As one court recently stated, "[t]o construe the Declaratory Judgment Act to permit a federal court to conduct a trial \textit{de novo} in reverse FOIA cases would transfer primary decisional responsibility for agency disclosures from the administrative agencies to the federal courts."\textsuperscript{73} Thus, it appears that the burden will be on the submitters of the data to show that release would involve an abuse of agency discretion.

\textbf{B. Arguments of the Submitters to Prevent Release of the Data by the FDA.}

The submitters of safety and effectiveness data might rely on several theories emanating from the FOIA, the Trade Secrets Act\textsuperscript{74} and the confidentiality provision of the Food, Drug and Cosmetic Act\textsuperscript{75} in an effort to prevent FDA disclosure of the data. Before the submitters can advance the intricacies of these theories, however, they must prevail on the threshold issue of whether the safety and effectiveness data falls within the protection of exemption 4 of the FOIA.\textsuperscript{76} That provision covers two kinds of material: first, trade secrets and, second, "information which is (a) commercial or financial, (b) obtained from a person, and (c) privileged or confidential. The exemption given by the

\textsuperscript{70}  See, e.g., Chrysler Corp. v. Brown, 99 S. Ct. 1705 (1979); Pennzoil Co. v. FPC, 534 F.2d 627 (5th Cir. 1976).
\textsuperscript{72}  Public Serv. Comm'n v. Wycoff Co., 344 U.S. 237, 246 (1952).
\textsuperscript{75}  21 U.S.C. § 331(j) (1976).
\textsuperscript{76}  5 U.S.C. § 552(b) (1976) provides in pertinent part:
This section does not apply to matters that are—
\begin{itemize}
  \item trade secrets and commercial or financial information obtained from a person and
  privileged or confidential.
\end{itemize}
Congress does not apply to information which does not satisfy the three requirements stated in the statute.\textsuperscript{77}

Almost all of the litigation over this exemption has dealt with the second part, while very few cases have construed the term "trade secrets." However, the confidentiality provision of the Food, Drug and Cosmetic Act refers to "any method or process which as a trade secret is entitled to protection,"\textsuperscript{78} and therefore it is necessary to determine whether safety and effectiveness data constitutes a trade secret.

Nowhere is the scope of the term "trade secret" definitively delineated for purposes of the FOIA. The legislative history contains no statement of congressional intent with respect to the coverage of the term in this context, nor has the Supreme Court ruled on the question. One definition, that of the Restatement of Torts, has received a great deal of attention. It states that a trade secret is "any formula, pattern, device or compilation of information which is used in one's business, and gives him an opportunity to obtain an advantage over competitors who do not know or use it."\textsuperscript{79} The Supreme Court, citing this definition as one "widely relied-upon,"\textsuperscript{80} applied it in a case involving a patent problem. Several lower federal courts have used the Restatement definition in exemption 4 cases,\textsuperscript{81} but that application has been mechanical and the courts have offered no explanation of the appropriateness of this definition as applied to the FOIA. Finally, the FDA itself relied upon the Restatement definition in the preamble to the Public Information Regulations.\textsuperscript{82}

An alternate definition of the term "trade secret" is found in \textit{Consumers Union of the United States, Inc. v. Veterans Administration}.\textsuperscript{83} In its discussion of the scope of the term "trade secret" in the context of disclosure prohibited by the Trade Secret Act,\textsuperscript{84} the court stated that it was aware of only one case-law definition: "an unpatented, secret, commercially valuable plan, appliance, formula, or process, which is used for the making, preparing, compounding, treating, or processing


\textsuperscript{78} 21 U.S.C. § 3310 (1976). See text accompanying notes 165-75 \textit{infra}.

\textsuperscript{79} \textit{RESTATEMENT OF TORTS} § 757, comment b (1939).

\textsuperscript{80} \textit{Kewanee Oil Co. v. Bicron Corp.}, 416 U.S. 470, 474 (1974).

\textsuperscript{81} \textit{See, e.g.}, Union Oil Co. v. FPC, 542 F.2d 1036, 1044 (9th Cir. 1976); \textit{Chevron Chem. Co. v. Costle}, 443 F. Supp. 1024, 1031-32 (N.D. Cal. 1978).


\textsuperscript{83} 301 F. Supp. 796 (S.D.N.Y. 1969), \textit{appeal dismissed as moot}, 436 F.2d 1363 (2d Cir. 1971).

Clearly, the Restatement definition is much broader than the one set forth in *Consumers Union*. Although both definitions require certain fundamental elements of trade secrecy—that the information be secret, commercially valuable, used in one's business and not generally known within the industry—the Restatement definition covers *any* kind of information that gives the possessor of the secret a commercial advantage. The more limited *Consumers Union* definition, on the other hand, protects only certain types of information (a “plan, appliance, formula, or process”) used for certain specified purposes (“the making, preparing, compounding, treating, or processing . . . of trade commodities”).

The arguments in favor of adopting the Restatement definition for FOIA purposes are centered around its comprehensiveness and its widespread usage. First, the FOIA exemptions, regardless of whether they are viewed as mandatory or permissive, are indicative of congressional concern for the protection of submitters’ information. The House report on the original FOIA states the purpose of the fourth exemption:

> This exemption would assure the confidentiality of information obtained by the Government through questionnaires or through material submitted . . . . It exempts such material if it would not customarily be made public by the person from whom it was obtained by the Government. The exemption would include . . . scientific or manufacturing processes or developments . . . . It would also include information which is given to an agency in confidence, since a citizen must be able to confide in his Government.

The exemption does, therefore, protect submitters of financial or commercial data to government agencies “from the competitive disadvantages which would result from its publication.” The Restatement definition, covering any kind of trade secret information that gives its holder a competitive advantage, conforms closely to the purpose of the

---

86. See text accompanying notes 47-53 supra.
87. Clement 593.
fourth exemption.

A second argument favoring application of the Restatement definition to safety and effectiveness data is based on the fact that the FDA has endorsed this definition in the past. The preamble to the 1974 FOIA regulations states:

[T]he Restatement definition of a trade secret should remain the basic guideline for application of this exemption from the Freedom of Information Act. The Supreme Court has recently noted that the Restatement definition of a trade secret is “widely relied upon,” . . . . The Commissioner [of Drugs] can find no reason why it should be utilized for determining commercial damages but not for purposes of the Freedom of Information Act.90

Although the agency cannot alter the provisions of the FOIA by its own express or implied promises of confidentiality,91 it was clearly the intent of Congress that agency practices and the expectations of the submitter should be considered in determining the applicability of the fourth exemption.92 In view of the FDA's endorsement of the Restatement definition, there is clear justification for reliance on that definition by the submitter.

A third reason for applying the Restatement definition is the fact that it is the most widely used definition of a trade secret and it has been adopted by many state courts and legislatures. In the absence of any definition in the FOIA, it can be implied that Congress intended the term to have the scope accorded to it by common use. Advocates of the narrower Consumers Union definition will argue that the Restatement definition, which evolved out of tort law dealing with breaches of trust by former employees, has no application to the FOIA. However, in view of the close conformity of the Restatement definition to the purpose of the fourth exemption, its endorsement by the FDA and its general acceptance, the court in construing the term “trade secret” in the context of the FOIA likely would adopt the Restatement definition.

If that definition were accepted, it seems clear that safety and effectiveness data would be found to constitute a trade secret. Although some argument could be made that the data is not a method or process93 as required under the narrower definition,94 it certainly is a “compilation of information.” Given the requirement for submission of the data in order to obtain a license to market the drug, there can be no

91. See note 88 supra.
93. The protocol itself clearly is a method or process.
94. See text accompanying notes 165-75 infra.
doubt that the data is "used in one's business." Finally, considering the
tens of millions of dollars generally required for the development of the
data, the knowledge contained in it and the resulting license if the
NDA is approved, the data clearly gives its developer "an advantage
over competitors who do not know or use it," especially in the case of
unpatented drugs.

The conclusion that safety and effectiveness data constitutes a
trade secret is strengthened by the recognition of a helpful distinction
between trade secrets and confidential commercial information. The
competitive advantage associated with a technological trade secret is
almost always jeopardized by any disclosure to competitors, even if the
source of the data is not revealed. Confidential commercial informa-
tion, on the other hand, can usually be released without any competi-
tive harm if the source of the data is withheld.95 Thus, for example,
affirmative action plans are always considered under the "confidential
commercial or financial information" part of exemption 4 and not as
trade secrets.96 Those plans would be of virtually no practical value to
competitors unless accompanied by information identifying the firm
implementing such plans. This is clearly not the case with safety and
effectiveness data. Publication without attribution would be as harmful
as release with attribution. In either case, data costing millions of dol-
lars to compile would be available to competitors for their own drug
development at no real cost. This would inevitably cause competitive
harm.97

1. The Material Falls Within Exemption 4 and Therefore Should
Not be Disclosed. Submitters seeking to protect the confidentiality of
safety and effectiveness data would first argue that the agency should
not be permitted to release material exempt from the disclosure re-

96. See, e.g., Sears, Roebuck & Co. v. Eckerd, 575 F.2d 1197 (7th Cir. 1978); General Dy-
namics Corp. v. Marshall, 572 F.2d 1211 (8th Cir. 1978), vaced and remanded, 99 S. Ct. 2024
(1979).
97. The question of the applicability of exemption 4 to safety and effectiveness data was
addressed in Morgan v. FDA [1974 Transfer Binder] FOOD DRUG Cos. L Rep (CCH) ¶ 41,147
(D.C. Cir. 1974). In that case, the plaintiff sought disclosure of safety and effectiveness data for
certain oral contraceptives. The FDA refused to disclose this information and argued that the
data fell within exemption 4. The agency was awarded summary judgment because the plaintiff
failed to contest the FDA's assertion that the data was either a trade secret or confidential com-
mercial information.

Here, of course, we are dealing with a situation in which the FDA is seeking to release the
criminal sanctions for the unlawful release of trade secrets, it is necessary to determine whether
safety and effectiveness data constitutes a trade secret. The Morgan court did not find it necessary
to address this issue.
quirements of the FOIA, especially when that disclosure could cause serious competitive harm. In cases seeking to force an agency to release rather than withhold data, courts have held that exemption 4 "may be invoked [by the agency] for the benefit of the person who has provided commercial or financial information if it can be shown that public disclosure is likely to cause substantial harm to his competitive position." The legislative history of the Act contains numerous indications of congressional intent to establish "workable standards for what records should and should not be open to public inspection."

Yet, despite this concern, most courts and the subsequent legislative history agree that the FOIA exemptions are permissive and that an agency decision to release information can be set aside only for an abuse of administrative discretion. In *Westinghouse Electric Corp. v. Schlesinger*, the Fourth Circuit Court of Appeals, which is known for its narrow reading of the permissible scope of disclosure under the FOIA, stated:

> So far as exempt information is concerned, the Act... "neither authorizes [n]or prohibits the disclosure of such information," and the disclosure of such exempt information is ordinarily discretionary with the agency. ... [W]hen review of an administrative decision to disclose is sought... under the APA, ... it is subject to reversal if arbitrary, capricious, an abuse of discretion "or otherwise not in accordance with law."  

Two tests are applied by the courts in determining whether an agency has abused its discretion by releasing data that falls within an exemption to the FOIA. If the agency’s decision is to be upheld, the court must first be assured that the decision was based upon a consideration of all relevant factors and that the reasons stated provide support for the decision. In making this determination, the court must be convinced that the agency has considered the possible harm to both the submitter of the data and the general public as a result of disclosure, as

---

100. See note 53 *supra* and text accompanying notes 47-53 *supra*. The Supreme Court has recently confirmed that the exemptions are permissive. *Chrysler Corp. v. Brown*, 99 S. Ct. 1705 (1979).
101. See text accompanying notes 68-70 *supra*.
102. 542 F.2d 1190 (4th Cir. 1976).
104. 542 F.2d at 1197-98 (quoting 5 U.S.C. § 706(2)(A) (1976)).
well as resulting benefits. The court will also want assurances from the agency that there is no alternative disclosure plan that could provide the benefits of disclosure with less harm to private and public interests.\textsuperscript{106}

If the FDA, after consideration of all relevant factors and alternatives, were to promulgate regulations providing for the disclosure of safety and effectiveness data based on its conclusion that the benefits of disclosure—opening up agency decision making, curtailing unnecessary and expensive duplicative testing, and sharing of scientific expertise—outweigh possible harms such as reduced incentive for research and development of new drugs, a court would probably defer to agency expertise and would not be willing to set the regulations aside under the first abuse-of-discretion test. The task of constructing the cost-benefit calculus lies with the agency and not the courts. If the FDA's evaluation of the impact of disclosure takes into account all relevant factors, it would be quite difficult for a judge to find that calculus incorrect. The instinct of a court when confronted with such a problem will almost inevitably be to defer to agency expertise. With regard to the FDA's present disclosure policy, one court noted that in promulgating the disclosure regulations, the agency was acting in an area "which directly concerns the realm of its special expertise and administrative experience. In reviewing the merits of the case this is an important consideration."\textsuperscript{107} The deference accorded to the FDA is probably greater than that given to other agencies because its decisions are usually based on very technical scientific analysis rather than legal or political theories and because of respect for medical decision making.\textsuperscript{108}

The second test of whether an abuse of administrative discretion has occurred requires a determination of whether the act complained of would constitute a violation of another statute. This was made clear in *Charles River Park "A", Inc. v. Department of Housing and Urban Development*.\textsuperscript{109} "[I]f the disclosure of the information involved here would constitute a violation of a criminal statute, it would be an abuse

\textsuperscript{106} Id. at 632.


\textsuperscript{108} This point was vividly made by one FDA observer:

[E]very experienced food and drug lawyer will tell you that in 999 out of 1,000 cases, even the most sanguine counsel knows that he hasn't a prayer of persuading an appellate court to second-guess the FDA....

It is indeed a sturdy appellate judge who is not tempted to clutch his stomach, to recall every episode of family illness, and to react in favor of those who march under the banner of protecting the aged, lactating mothers, and infant children.

\textsuperscript{Austern, Sanctions in Silhouette: An Inquiry Into the Enforcement of the Federal Food, Drug, and Cosmetic Act, 51 CAL. L. REV. 38, 45 (1963).}

\textsuperscript{109} 519 F.2d 935 (D.C. Cir. 1975).
of discretion for an agency to ignore such a statutory mandate and re-
lease the information." Thus, before the FDA can release safety and
effectiveness data, it must be shown that disclosure would violate
neither the Trade Secrets Act nor the Food, Drug and Cosmetic
Act.

2. The Trade Secrets Act Prohibits Release. The submitters' sec-

110. Id. at 942.
112. The confidentiality provision of the Food, Drug and Cosmetic Act is found at 21 U.S.C.
§ 331(j) (1976).

That the FOIA should not be construed to overrule statutes prohibiting disclosure is a con-
cern expressed throughout the Act's legislative history. This concern is written into the Act itself,
and exemption 3 states that the Act "does not apply to matters that are . . . specifically exempted
from disclosure by statute . . . provided that such statute (A) requires that the matters be withheld
from the public in such a manner as to leave no discretion on the issue, or (B) establishes particular
criteria for withholding or refers to particular types of matters to be withheld." 5 U.S.C.
§ 552(b)(3) (1976) (emphasis added).

There has been disagreement whether 18 U.S.C. § 1905 (1976), the Trade Secrets Act, falls
within the scope of exemption 3. In FAA v. Robertson, 422 U.S. 255 (1975), the Supreme Court
ruled that the exemption did cover a provision of the FAA Act that gave the agency blanket
discretion to withhold information. Congress reacted to Robertson by amending exemption 3 to
read as quoted above in order to narrow its scope to those statutes that require withholding of
specific information. Most courts have held that exemption 3 "does not incorporate section 1905
into the FOIA in such a way as to make section 1905 broader than the fourth exemption." Charles
River Park "A", Inc. v. Department of HUD, 519 F.2d 935, 941 n.7 (1975). Thus, the test for
purposes of exemption 3 is whether the information falls within both exemption 4 and § 1905.
Id.

This approach of the Charles River Park court was cited with approval
by the House Committee on Government Operations in its consideration of the Government in the Sunshine Act, Pub. L.
U.S.C.):

[If] material did not come within the broad trade secrets exemption contained in the
Freedom of Information Act, section 1905 would not justify withholding; on the other
hand, if material is within the trade secrets exemption of the Freedom of Information
Act and therefore subject to disclosure if the agency determines that disclosure is in the
public interest, section 1905 must be considered to ascertain whether the agency is for-
bidden from disclosing the information.

Ad. News 2183, 2205; see National Parks & Conservation Ass'n v. Kleppe, 547 F.2d 673, 686-87
(D.C. Cir. 1976). One court noted that the legislative history on the 1976 amendment "indicate[s]
that one of the purposes . . . is to assure that § 1905 is not considered to be within the ambit of
Another court recently declared that "§ 1905 does not qualify as an exemption 3 statute." Nation-

Thus, it remains to be determined only that safety and effectiveness data falls within the
scope of section 1905. This question is addressed in the next section of the Comment.

As for 21 U.S.C. § 331(j) (1976), the confidentiality provision of the Food, Drug and Cosmetic
Act, there is no question that it is specific and narrow enough to qualify as an exemption 3
statute. Thus, even if safety and effectiveness data is found not to be exempt from the FOIA
through exemption 4, it would be exempt from the Act through exemption 3. If safety and effec-
tiveness data is protected by section 331(j). That question is addressed in the text accompanying
notes 165-75 infra.
ond line of defense would be the argument that release of safety and effectiveness data would violate the Trade Secrets Act,\textsuperscript{113} 18 U.S.C. § 1905, which prohibits any disclosure of protected material (relating to trade secrets or confidential statistical data) that is "not authorized by law."

The first question to be addressed is whether section 1905 and exemption 4 are coextensive. In the view of the FDA, the scope of the two sections is practically identical:

The Commissioner [of Drugs] concludes that it is not feasible or practical to determine the differences, if any, between the confidentiality provisions in 18 U.S.C. [§] 1905 . . . and in the Freedom of Information Act. If there are any differences, they are extremely subtle and small. Accordingly, the Commissioner intends . . . to regard the coverage of these provisions as identical.\textsuperscript{114}

Several courts have also found the two provisions to be identical. They have done so, however, by misreading both precedent and legislative history. In \textit{Westinghouse Electric Corp. v. Schlesinger},\textsuperscript{115} the court stated that

it has been uniformly held that the scope of § 1905 and Exemption 4 of the FOIA are . . . the 'same' or . . . "co-extensive." Accordingly, material qualifying for exemption under (b)(4) falls within the material, disclosure of which is prohibited under § 1905. And this was the specific holding in \textit{Charles River Park} . . . .\textsuperscript{116}

Yet, the \textit{Charles River Park} court held only that "if" the disclosure

\begin{itemize}
\item \textsuperscript{113} 18 U.S.C. § 1905 (1976) provides:
\begin{quote}
Whoever, being an officer or employee of the United States or of any department or agency thereof, publishes, divulges, discloses, or makes known in any manner or to any extent not authorized by law any information coming to him in the course of his employment or official duties or by reason of any examination or investigation made by, or return, report or record made to or filed with, such department or agency or officer or employee, thereof, which information concerns or relates to the trade secrets, processes, operations, style of work, or apparatus, or to the identity, confidential statistical data, amount or source of any income, profits, losses or expenditures of any person, firm, partnership, corporation, or association; or permits any income return or copy thereof or any book containing any abstract or particulars thereof to be seen or examined by any person except as provided by law; shall be fined not more than $1,000 or imprisoned not more than one year, or both; and shall be removed from office or employment.
\end{quote}

\item \textsuperscript{114} 39 Fed. Reg. 44,602, 44,612 (1974). In a suit challenging the agency’s procedure for notification of submitters when there is a FOIA request for their information, the FDA agreed that the provisions of § 1905 and exemption 4 are "for the purposes of this suit, the same." \textit{Pharmaceutical Mfrs. Ass’n v. Weinberger}, 401 F. Supp. 444, 446 (D.D.C. 1975).
\begin{quote}
This reasoning was criticized in \textit{Pendergast}, \textit{Problems and Opportunities Under the Public Information Regulations of the FDA}, 30 Food, Drug & Cosm. L.J. 326, 334 n.35: "The FDA cites no authority for this conclusion and it could lead to trouble. The distinction may be, as the FDA says, ‘subtle,’ but subtle differences can cause major arguments.”
\end{quote}

\item \textsuperscript{115} 542 F.2d 1190 (4th Cir. 1976), \textit{cert. denied}, 431 U.S. 924 (1977).
\item \textsuperscript{116} 542 F.2d at 1204 n.38 (citations omitted).
\end{itemize}
of the information involved here would constitute a violation of a criminal statute, it would be an abuse of discretion for an agency to ignore such a statutory mandate and release the information."\textsuperscript{117} In fact, *Charles River Park,* in a footnote to which the *Westinghouse* court refers, clearly indicates that section 1905 and exemption 4 are not of the same scope: "Since only the FOIA's fourth exemption deals with matters covered by section 1905, consideration of section 1905 in FOIA cases is appropriate only when the information falls both within the fourth exemption and under section 1905."\textsuperscript{118} This statement implies that the two provisions are not identical in scope. If they were, the court probably would have simply stated that the only inquiry must be whether the release is "authorized by law."\textsuperscript{119}

Similarly, the court in *Westchester General Hospital, Inc. v. Department of Health, Education and Welfare*\textsuperscript{120} found that section 1905 and exemption 4 "are equivalent in scope."\textsuperscript{121} This conclusion, like that in *Westinghouse,* was based on *Charles River Park,* but the court went on to quote legislative history in defense of its finding. It claimed that the following statement from the House report on the 1976 amendments to the FOIA shows the congruence of the two provisions: "[I]f material did not come within the broad trade secrets exemption contained in the Freedom of Information Act, section 1905 would not justify [nondisclosure] . . . ."\textsuperscript{122} However, this passage only indicates that section 1905 is not broader than exemption 4. It clearly leaves open the possibility that data can be exempt from the FOIA through exemption 4 and still be disclosed, at the agency's discretion, in situations where section 1905 does not apply. The House report relied upon in *Westchester General Hospital* goes on to make this point. Immediately after the section quoted by the court, the report states that "if material is within the trade secrets exemption . . . and therefore subject to disclosure if the agency determines that disclosure is in the public interest, section 1905 must be considered to ascertain whether the agency is forbidden from disclosing the information."\textsuperscript{123} Again, were the provisions identical in scope, Congress could have stated more precisely that the only question

\textsuperscript{117} 519 F.2d at 942 (emphasis added).
\textsuperscript{118} Id. at 942 n.7 (emphasis added).
\textsuperscript{119} See text accompanying notes 148-64 infra.
\textsuperscript{120} 434 F. Supp. 435 (M.D. Fla. 1977).
\textsuperscript{121} Id. at 439.
was whether the disclosure was authorized.

The contention that exemption 4 is broader than section 1905 might, at first glance, seem erroneous. Whereas the former protects trade secrets and certain privileged commercial or financial information, the release of which would cause serious competitive harm, the latter seemingly protects anything that "concerns or relates to . . . trade secrets," as well as a list of other kinds of information. This dilemma is resolved by examining the historical roots of the present section 1905, enacted as part of the 1948 codification of the federal criminal code. The new section combined three preexisting laws: first, an income tax statute prohibiting disclosure of any data (including the operations of any business) gathered in the course of an IRS investigation or found in tax returns; second, a tariff commission statute forbidding disclosure of "trade secrets . . . embraced in any examination or investigation" by the Tariff Commission; and, finally, a statute directing the Commerce Department not to disclose "statistical information furnished in confidence to the Bureau of Foreign and Domestic

125. See note 113 supra and accompanying text.

|It shall be unlawful for any collector, deputy collector, agent, clerk or other officer or employee of the United States to divulge or to make known in any manner whatever not provided by law to any person in the operations, style of work or apparatus of any manufacturer or producer visited by him in the discharge of his official duties, or the amount or source of income, profits, losses, expenditures, or any particular thereof, set forth or disclosed in any income return . . . , or to permit any income return or copy thereof or any book containing any abstract or particulars thereof, to be seen or examined by any person except as provided by law; and it shall be unlawful for any person to print or publish in any manner whatever not provided by law any income, return, or any part thereof or source of income, profits, losses, or expenditures appearing in any income return; and any offense against the foregoing provision shall be a misdemeanor and be punished by a fine not exceeding one-thousand dollars or by imprisonment not exceeding one year, or both, at the discretion of the court; and if the offender be an officer or employee of the United States he shall be dismissed from office and be incapable thereafter of holding any office under the Government.


|It shall be unlawful for any member of the commission, or for any employee, agent, or clerk of the commission, or any other officer or employee of the United States, to divulge, or to make known in any manner whatever not provided for by law, to any person, the trade secrets or processes of any person, firm, copartnership, corporation, or association embraced in any examination or investigation conducted by the commission, or by order of the commission, or by order of any member thereof. Any offense against the provisions of this section shall be a misdemeanor and be punished by a fine not exceeding $1,000, or by imprisonment not exceeding one year, or both, in the discretion of the court, and such offender shall also be dismissed from office or discharged from employment.
Commerce."

Much of the original language of these statutes has been incorporated into section 1905, but, "taken literally, the consolidated version . . . has a tremendously broader scope than the original three statutes."

Nevertheless, according to the legislative history of the codification statute, it was not the intent of Congress "to create any substantive changes in existing criminal statutes but merely to rearrange and consolidate them." The Senate report states that the purpose of the 1948 revision was to make it "easy to find the criminal statutes because of the arrangement, numbering, and classification. The original intent of Congress is preserved." In addition, the Reviser's Notes in the House report indicate that, with respect to the three statutes combined in section 1905, only "[m]inor changes were made in translations and phraseology."

The Supreme Court has recognized that the 1948 codification of the criminal code was not designed to bring about substantive change in the criminal laws. In United States v. Cook, the Court examined the effect of codification on an embezzlement statute. The Court stated: "The general purpose of the new Code was to 'codify and revise . . . The original intent of Congress is preserved,' . . . and . . . the reviser's note . . . disclosed no intention of making any change in the substantive content or the coverage of the law." As one commentator has argued, "[t]he Cook decision supports the proposition that the 1948 codification statute should not be interpreted as having created any substantive change in the meaning of the predecessor nondisclosure statutes . . . . [T]he [new] statute should be interpreted according to the legislative intent underlying the original statute[s]."

Thus, it appears that the scope of section 1905 is much narrower.
than its language would indicate. It is, as the legislative history of the 1976 FOIA amendment recognizes, much narrower than the FOIA's fourth exemption. This conclusion is corroborated by the very nature of the provisions; the fourth exemption merely creates an area for the exercise of administrative discretion, while section 1905 is a criminal statute that must be construed narrowly. Should this historical view of the scope of section 1905 be accepted, it clearly would not prohibit disclosure of safety and effectiveness data, for that data is not collected in the course of tax or tariff activity or submitted to the Bureau of Foreign or Domestic Commerce.

Even if this historical analysis is rejected, it does not necessarily follow that disclosure of safety and effectiveness data by the FDA would be prohibited by section 1905. One reason is that it is not clear whether section 1905 was intended to limit an agency's authority to disclose information. Perhaps it was the intent of Congress not to restrict agency action, but simply to penalize unauthorized disclosure by individual employees. If so, FDA disclosure of safety and effectiveness data in accordance with properly promulgated regulations would not constitute a violation of section 1905.138 There is no definitive answer to what the Seventh Circuit Court of Appeals in Sears, Roebuck and Co. v. Eckerd called this "difficult and as yet unresolved question." Yet, the Sears court offered two reasons for viewing the provision as restricting unauthorized individual acts and not agency decision making. First, the legislative history of the income tax statute that was codified as section 1905 indicates that one of the primary concerns of Congress was the untrustworthiness of tax officials. That statute, originally enacted in 1864, was modified by the Tariff Act of 1894, another part of which required corporations to maintain financial records for inspection by tax officials. In the context of the latter section, Senator Aldrich, in a statement partially quoted by the Sears court, emphasized the need to constrain individual agents: "The secrets of the business of every corporation in the United States are practically to be made known to competitors or made public by this

---

137. See text accompanying notes 122-23 supra.
139. 575 F.2d 1197 (7th Cir. 1978).
140. Id. at 1201.
141. See note 127 supra.
143. Ch. 349, § 34, 28 Stat. 509.
144. Id. §§ 35-36.
145. 575 F.2d at 1201.
provision. . . . [These secrets] are to be turned over to the tender mercies of poorly paid revenue agents.”

Second, the Sears court noted that there are no provisions for penalizing or restraining the agency. “Even if the legislative history were unclear,” the court reasoned, “limiting the statute’s focus to actions by agency employees seems more consistent with the statutory scheme because the enforcement mechanism of the statute provides only penalties for guilty individuals and offers no restraint on agency action.”

A second reason why the FDA’s disclosure of safety and effectiveness data would not necessarily be prohibited by section 1905 is that, regardless of the section’s focus, it does not absolutely prohibit disclosure of information that comes within its scope, but merely precludes disclosures that are “not authorized by law.” Clearly, the FOIA cannot provide the necessary authorization for the hypothetical disclosure regulations allowing FDA release of safety and effectiveness data because the Act “does not apply” to material that falls within the FOIA’s fourth exemption. But, anticipating that problem, it was hypothesized that the regulations were promulgated under section 301 as well. Thus, the question posed is whether regulations under section 301 would be regarded as “authorization by law” for the purpose of avoiding the prohibitions of section 1905.

In authorizing agency regulations for “the custody, use, and preservation of its records, papers, and property,” section 301 makes no reference to the permissible scope of disclosure of data held by an agency. In 1958, because of concern that agencies were using this general housekeeping provision as authority to withhold information from the public, the statute was amended to include a second sentence: “This section does not authorize withholding information from the public or limiting the availability of records to the public.” Another amendment that would have added “nor shall this section be construed as requiring the giving of information or the making of records avail-

146. 26 CONG. REC. 6893 (1894), quoted in Clement 610 n.100.
147. 575 F.2d at 1201. But see Chrysler Corp. v. Brown, 99 S. Ct. at 1716.
148. See note 113 supra and accompanying text.
150. See text accompanying notes 44-50 supra. The Supreme Court has just ruled that § 301 “was not intended to provide authority for limiting the scope of § 1905. Chrysler v. Brown, 99 S. Ct. at 1721-22.
152. “It appears that this section has been used too often by too many Government departments, agencies, and officials as an excuse for withholding information from the general public.” 104 CONG. REC. 6548 (1958) (statement of Rep. Brown).
able" was rejected.\textsuperscript{154}

The legislative debates on the 1958 amendment shed no light on whether regulations under section 301 can authorize release of data covered by section 1905. The chief proponent of the amendment, Representative Moss, stated that the amendment “does not affect the confidential status of information given to the Government and carefully detailed in . . . section 1905.”\textsuperscript{155} Another supporter said that “it would still be a violation of law for any agency of Government or any Government official to make public any of the records for which secrecy is provided by any of some 78 separate statutes.”\textsuperscript{156} Thus, the 1958 amendment was not intended to change government policy. “It merely defines the intent of the Congress which, in 1789, first voted this housekeeping authority. . . . It says to the departments of Government ‘if you desire to withhold the information from anyone, including the Congress, then seek specific authority.’”\textsuperscript{157} Unfortunately, the question whether section 1905, which specifically states that disclosures that are authorized by law are permissible, was subject to section 301 regulations was never addressed.

Not surprisingly, the federal circuit courts are in conflict over this issue. In \textit{Charles River Park}, the D.C. Circuit held that “[s]ection 301 does not authorize regulations limiting the scope of section 1905.”\textsuperscript{158} This finding was based on the fact that the 1958 amendment was not intended to affect section 1905.\textsuperscript{159} Yet this leaves unresolved the question whether the pre-1958 housekeeping provision would authorize such regulations. One commentator has argued that “past interpretations of section 1905 and other similar nondisclosure statutes imply that agency regulations constitute one form of law capable of authorizing disclosure within the meaning of section 1905.”\textsuperscript{160} This approach was accepted by the Third Circuit, and in \textit{Chrysler Corp. v. Schlesinger}\textsuperscript{161} the court wrote:

\begin{quote}
We have been referred to no legislative history suggesting that § 1905, a 1948 codification of a group of statutes applicable to specific agencies, was intended to limit the longstanding rulemaking au-
\end{quote}

\begin{footnotes}
\item[155] \textit{Id.} 6550.
\item[156] \textit{Id.} 6548 (remarks of Rep. Brown).
\item[157] \textit{Id.} 6550 (remarks of Rep. Moss).
\item[158] 519 F.2d at 942-43.
\item[159] See text accompanying note 155 supra.
\item[160] Clement 618-19 (footnote omitted). This commentator notes that “as early as 1864 administrative orders issued pursuant to § 1905’s predecessor income tax nondisclosure statute authorized and restricted disclosure of tax-related information.” \textit{Id.} 619 n.136.
\end{footnotes}
authority under the 1874 codification of the housekeeping statute... 
Congressman Moss only stated that the amendment would not affect the confidential status of information covered by § 1905. Such an interpretation of the 1958 amendment is totally at odds with its central purpose—the elimination of governmental secrecy—as it would transmogrify § 1905 into a weapon for those parties who advocate government secrecy. Thus... § 301 is a separate source of agency authority for the promulgation of disclosure regulations and... disclosures pursuant to such regulations are authorized by law and immune from the prohibitions of § 1905.162

In *Sears, Roebuck & Co. v. Eckerd*,163 the Seventh Circuit specifically concurred in this view. The Supreme Court, however, rejected this analysis in *Chrysler Corp. v. Brown*.164

The foregoing discussion indicates that it would be quite difficult for the submitters of safety and effectiveness data to prevail on the contention that the Trade Secrets Act prevents FDA disclosure of that data. They would have to convince a court, first, that the proper scope of section 1905 would encompass all matters relating to trade secrets and not just those protected in the statutes which were incorporated into the 1948 codification; second, that section 1905 is addressed to disclosure by official agency action as well as unauthorized acts of individual employees; and, finally, that regulations properly promulgated under section 301 would not constitute "authorization by law" for purposes of section 1905. The Supreme Court has recently given the submitters ammunition on the last two points. The first question, however, remains open.

3. The Confidentiality Provision of the Food, Drug and Cosmetic Act Prohibits Release. The submitters' third line of argument would be that disclosure of safety and effectiveness data is prohibited by the confidentiality provision of the Food, Drug and Cosmetic Act, section 331(j), which prohibits "[t]he using by any person to his own advantage, or revealing, other than to the Secretary or officers or employees of the Department [of HEW], or to the courts when relevant in any judicial proceeding under this chapter, any information... concerning any method or process which as a trade secret is entitled to protection."165 The scope of section 331(j) has not been clearly delineated by the courts, and the legislative history is quite ambiguous on this matter.

On its face, the statute does not protect all trade secrets, but only those *methods or processes* that qualify as trade secrets. However,

162. 565 F.2d at 1187 (footnotes omitted).
163. 575 F.2d 1197 (7th Cir. 1978).
neither Congress nor the FDA seems to have consistently adhered to this view. In the 1962 revision of the Food, Drug and Cosmetic Act, the House of Representatives passed a provision that would have expanded the scope of section 331(j) to cover all trade secrets acquired by the FDA. The Senate, fearing that such a provision would inhibit FDA efforts to warn the public regarding potential dangers, rejected that provision. This change was not included in the final version of the Act, but the conference report does contain a statement indicative of a congressional belief that section 331(j) already encompassed all trade secrets:

> It is expected, of course, that since the Congress is not making the law more restrictive on this matter, the FDA will not make its interpretation and administration of [the] section . . . more restrictive. Congress and the public deserve to have access to information in the Food and Drug Administration which is not of the nature of a trade secret and is in the public interest.

At that time, the FDA also maintained that the protection of section 331(j) should not be limited to methods and processes. In fact, the FDA's position, as reflected in an in-house memorandum in 1960, was clearly overbroad:

> [The FDA] has uniformly treated all material submitted to it in new drug applications as being confidential whether or not 'trade secrets' were involved . . . . [This relieves the FDA] of the risk of having to determine whether or not every particular piece of information is or is not a 'trade secret' . . . .

In the 1974 Public Information Regulations, the FDA recognized the need for a somewhat narrower construction of the scope of section 331(j), but still insisted that all trade secrets, not just methods and processes, were protected. It seems, however, that the FDA was not very certain of this stance. It fell back upon "the consistent administrative interpretation that this statutory provision can encompass animal and human [safety and effectiveness] data" and concluded that because of that "longstanding interpretation," release of safety and effec-

169. Memorandum from William F. Goodrich, Assistant General Counsel, FDA, to Bill V. McFarland, Assistant Director, Division of Federal-State Relations, FDA (1960), quoted in INTERIM REPORT 8.
171. Id. 44,602.
tiveness data would be improper. The agency was apparently unsure of the validity of this argument and continued, "regardless of the scope of section 331(j) ... the provisions of 18 U.S.C. 1905 and the trade secrets exemption of the Freedom of Information Act are clearly applicable to such data." It has been shown, however, that these statutes do not necessarily preclude disclosure.

Clearly, the nondisclosure requirement of section 331(j), which covers any "method or process which as a trade secret is entitled to protection," would apply to the test protocols or the designs for safety and effectiveness experiments. These protocols are certainly methods or processes and would constitute trade secrets to the extent that the testing practices are not generally known in the industry. The fact that certain companies are able to obtain FDA approval for new drugs much more quickly than others indicates that innovative testing techniques are of great commercial value and should qualify as trade secrets. However, it is not clear that this protection should extend to the scientific findings resulting from the safety and effectiveness trials. As Theodore Cooper, then Assistant Secretary of HEW for Health, stated to Congress:

[Safety and effectiveness data in new drug applications] should not be regarded as trade secrets or proprietary information. The Department believes that the concept that animal and human data on safety and effectiveness of a drug are proprietary information belonging to a single manufacturer should not be supported because of the enormous social and economic costs of such a policy. This concept creates an impression of secrecy and generates unnecessary and duplicative human research. Consideration of safety and effectiveness data as trade secrets appears to serve a competitive and economic purpose for which the patent laws are more properly intended. We believe, therefore, that scientific data relating to safety and effectiveness of a drug should be in the public domain, while, at the same time, we continue to support the view that manufacturing methods and processes are properly considered as trade secrets.

Thus, here too, the validity of the submitters' argument that the law forbids disclosure of safety and effectiveness data is uncertain. However, given the breadth of past constructions of section 331(j) and the apparent congressional recognition in 1962 that the confidentiality of all trade secrets was to be protected by the FDA, this argument for the protection of safety and effectiveness data may be successful.

172. *Id.* 44,634-35.
173. *Id.* 44,635.
In reviewing the legal theories available to the submitters of safety and effectiveness data, one must conclude that their arsenal against disclosure of the data under properly promulgated regulations is uncertain. The FOIA, though not authorizing release, would not prevent it. It is questionable whether the protection of the Trade Secrets Act would be sufficient to prohibit disclosure under properly promulgated regulations. Finally, it is not clear that safety and effectiveness data would constitute a “method or process” and thus qualify as a trade secret protected under the Food, Drug and Cosmetic Act. Therefore, if the FDA were to conclude that release of this information would be in the public interest and would not place undue burdens on the drug industry, a court might very well recognize the agency’s expertise and refuse to find an abuse of discretion. The courts are generally loath to substitute their judgment for agency expertise in this area.175

IV. THE POLICY IMPLICATIONS OF RELEASE OF SAFETY AND EFFECTIVENESS DATA

Although the FDA might well be able to release safety and effectiveness data submitted with new drug applications under present law, it does not necessarily follow that such disclosure would be sound on public policy grounds. In addition to its uncertainty as to the legality of disclosure, the FDA has consistently refused to authorize full disclosure of the data due to its belief that such a decision should be left to Congress.176 That question is now before Congress as part of the Drug Regulation Reform Bill.177 The remainder of this Comment will show that the disclosure rules in the proposed legislation are likely to have a substantial adverse impact on research and development of new drugs and exacerbate the problem of drug lag, and an alternative scheme for disclosure of the data will be presented. As a preliminary matter, how-

175. See note 108 supra and text accompanying notes 107-08 supra.
177. S. 2755 and H.R. 11611, 95th Cong., 2d Sess. (1978). These bills were reintroduced in the present Congress, S. 1045 and H.R. 4258, 96th Cong., 1st Sess. (1979). Identical versions of the bill drafted by the Carter Administration were originally filed in each house on March 16, 1978. The Senate bill, S. 2755, was referred to the Subcommittee on Health of the Committee on Human Resources; the House bill, H.R. 11611, was referred to the Subcommittee on Public Health and the Environment of the Committee on Interstate and Foreign Commerce. The bills were introduced by the chairmen of those subcommittees, Senator Kennedy and Representative Rogers. The bill was drafted by the FDA after conducting extensive public hearings, and it represents an effort to enact a compromise bill. The bill contains some reforms for which industry has lobbied heavily, such as easier and cheaper procedures to obtain a license to market new drugs. 36 CONG. Q. 689-93 (1978). Yet, the provisions in the bill allowing for the release of safety and effectiveness data have annoyed the industry to such an extent that the president of the Pharmaceutical Manufacturers Association has remarked, “If we had to say the administration bill or none at all, we would say none.” Id. 689.
ever, a brief overview of the economics of research and development in the drug industry will be helpful.

A. The Economics of Pharmaceutical Research.

In few other major industries is research and development as significant as it is in the drug industry. It is important to both the individual companies and the public. The American pharmaceutical industry is the most prolific source of new drugs in the world. Between 1963 and 1970, for example, over 80% of the new drugs introduced originated from domestic drug research.\(^{178}\) The price of that originality, however, is high. It now costs an average of $50 million and takes eight to ten years to develop and obtain approval to market a new drug.\(^{179}\)

Studies of pharmaceutical research employ a model that divides drug companies into two groups: research intensive and non-research intensive.\(^{180}\) The FDA’s own study of the effect of the release of safety and effectiveness data uses the criterion of a $10 million expenditure for research and development in 1975 as the classifying factor.\(^{181}\) The studies have also shown that a company’s retail sales provide a good indication of the amount of money a firm will spend on research and development. It was found that research-intensive firms spend approximately 8-10% of their retail sales on research and development, while non-research-intensive firms spend only 4-5% of their retail sales in this area.\(^{182}\) But because the research-intensive firms tend to be the larger companies, the difference in the amount of money spent by the two groups is much more dramatic than the percentages might indicate. The average research-intensive firm devoted nearly $37.5 million to global research and development in 1975, while non-research-intensive firms spent an average of only $2.9 million.\(^{183}\) Thus, the twenty-five research-intensive firms in the FDA study spent 93% of the research dollar, while the twenty-four non-research-intensive firms spent only 7%. While this indicates that research and development is concentrated in the larger companies, it does not tell the whole story. Other studies have shown that research output, measured in terms of the “new chemical entities” (NCEs) marketed, is even more concentrated. From 1957 to 1961, the four most productive research firms provided 46.2% of the

---

180. Both the Pracon Study and Dworkin apply this analysis.
181. Dworkin 5.
182. Id. 7; Pracon Study 61.
183. Dworkin 5.
innovational output; for the years 1967 through 1971 that figure was 61%.184 Given this concentration, it is clear that smaller companies are finding it less productive to invest substantial sums in research and development.

A related problem is the marked decrease in the number of new products discovered. Despite the fact that research, in constant dollars, grew by 56% between 1965 and 1974, the number of new products actually developed declined by 26%.185 There are several possible explanations for this decline in the productivity of research. Among them are higher costs due to increased regulation by the 1962 amendments to the Food, Drug and Cosmetic Act, exhaustion of profitable research opportunities, and plain bad luck. Thus, it is not surprising to note that financial analysts have questioned the adequacy of the return on investments in drug research.186 As one study noted, “[t]hose few firms which continue to operate large and expensive R & D programs must be able to demonstrate the viability of the research-intensive strategy in an increasingly negative environment. Otherwise management will have little alternative but to cut back on such spending in favor of more productive investments.”187 To the extent that research output is related to research input, this would result in even fewer new drugs.

Another problem in the area of new drugs is the “drug lag.” This term refers to the interval between the time when drugs are marketed somewhere in the world and the time when they are marketed in the United States. One study has noted that of all drugs available in both the United States and the United Kingdom by 1971, two-thirds were available first in the United Kingdom.188 This delay in the introduction of new drugs has been one of the major criticisms leveled at the FDA. It is only in the context of these problems—declining return on investment in research and development and drug lag—that the policy of disclosing safety and effectiveness data can be evaluated.


The disclosure provisions of the proposed legislation189 represent a

---

184. Pracon Study 32 (using data from Grabowski & Verron, Consumer Protection Regulation in Ethical Drugs, AMER. ECON. REV. (Feb. 1977)).
185. Pracon Study 30.
186. See id. 37-42.
187. Id. 39.
marked departure from present policy. A firm seeking to market a new drug would be required to submit three reports.\textsuperscript{190} The first report would contain a summary of each investigation conducted "to evaluate the effectiveness of the drug entity and to assess its risk,"\textsuperscript{191} and would state the basis for the submitter's belief that the drug is safe and effective.\textsuperscript{192} This report would be made available to the public at the beginning of the FDA review process when the petition to market has been formally filed.\textsuperscript{193} The second report would include a detailed description and the protocol for each investigation and "tables, compilations, and analyses of all data and information . . . relevant to the evaluation of the effectiveness of the drug entity and the assessment of its risks."\textsuperscript{194} This report, and the third report which would contain \textit{all} data compiled in the testing,\textsuperscript{195} would be made available to the public in two stages. When the petition is filed these reports could be disclosed to, but not copied by, persons who seek to participate in a public hearing on the petition so long as they are not connected with any competitor, disavow any commercial purpose and are willing to take security precautions to assure that no competitor will gain access to the information.\textsuperscript{196} These reports would be available to everyone, however, when the petition to market the new drug is granted.\textsuperscript{197} But, even though all competitors would have access to the data at that point, they could not use the data in support of their own petitions to the FDA for a period of five years.\textsuperscript{198}

\textbf{C. The Arguments in Support of the Proposals.}

Advocates of release of the data have several goals in mind. First, disclosure of the data would have the effect of opening up FDA decision making. The decisions that the agency makes regarding the marketing of new drugs play a major role in the development of overall health policy in this country, but without access to the data upon which those decisions are based, the public cannot offer any input into those decisions. Congress, through the FOIA and related legislation, has recognized the need for public awareness of the manner in which policy decisions are made. Yet, because of the secrecy surrounding evalua-

\begin{itemize}
\item \textsuperscript{190} \textit{Id.} § 111(b)(1)(B).
\item \textsuperscript{191} \textit{Id.}
\item \textsuperscript{192} \textit{Id.} § 111(b)(1)(B)(i).
\item \textsuperscript{193} \textit{Id.} § 111(b)(2)(A).
\item \textsuperscript{194} \textit{Id.} § 111(b)(1)(B)(ii).
\item \textsuperscript{195} \textit{Id.} § 111(b)(1)(B)(iii).
\item \textsuperscript{196} \textit{Id.} § 111(j)(3).
\item \textsuperscript{197} \textit{Id.} § 111(j)(2)(B).
\item \textsuperscript{198} \textit{Id.} § 121(b).
\end{itemize}
tions of new drug applications, the FDA is able to avoid compliance with the spirit of the legislation favoring open government. This secrecy is no more appropriate in scientific areas than it is in clearly political ones: "[T]he public’s need for information is especially great in the field of science and technology, for the growth of specialized scientific knowledge threatens to outstrip our collective ability to control its effects in our lives."\(^{199}\) Opening up FDA decision making, it is suggested, will lead to a more satisfactory resolution of the issues facing the agency; the more information that is available to the public, the greater the public’s ability to hold the agency accountable for its decisions. In addition, making information available to outside experts will probably mean that the agency will have access to more evidence upon which to base its decisions.

A second consideration is the fact that release of the data may serve to make the agency less risk adverse. One of the major criticisms of current FDA decision making is that the pressures on agency officials are one-sided.\(^{200}\) Because the adverse consequences an official would encounter by approving a less than “safe” drug are so much more severe than the problems encountered by ordering delay or further testing, regardless of the public’s need for the drug, the message to FDA officials is crystal clear. The external pressures on officials thus dictate risk-adverse behavior. As former FDA Commissioner Schmidt has noted:

[In all of FDA’s history, I am unable to find a single instance where a Congressional committee investigated the failure of FDA to approve a new drug. But, the times when hearings have been held to criticize our approval of new drugs have been so frequent that we aren’t able to count them. . . . The message of FDA staff could not be clearer. Whenever a controversy over a new drug is resolved by its approval, the Agency and the individuals involved likely will be investigated. Whenever such a drug is disapproved, no inquiry will be made. The Congressional pressure for our negative action on a new drug applications is, therefore, intense. And it seems to be increasing, as everyone is becoming a self-acclaimed expert on carcinogenesis and drug testing.\(^{201}\)]

The point is that the public might be more willing to accept some risks in new drugs than the FDA believes. By making known its willingness to accept certain risks when accompanied by certain possible corresponding benefits, the public might be able to influence the FDA to

---

200. H. GRABOWSKI, supra note 188, at 76.
approve or at least seriously to consider drugs that it might otherwise reject.

A third argument favoring release of safety and effectiveness data is that it would decrease the amount of expensive, duplicative testing. Since the data of one experimenter would be available to all once the experimental results had been accepted, there would be no need for others to spend the money and time required merely to duplicate the results. The data, it is felt, is scientific knowledge that should not be hoarded. Sharing of data as proposed in the legislation, with a five-year ban on use of the data by another company, would protect the primary submitter's research investment while lowering the cost of research and development for everyone. This compromise thus deals with both the rapidly rising costs of research and development and the uncertainty of return on investment.

Fourth, the sharing of information in this protected manner would stimulate competition in the marketing of generic drugs. Once the patent on a new drug has expired, competitors, already having access to the requisite safety and effectiveness data, would encounter few, if any, barriers to entry in the market for that drug. This competition would put an effective end to the monopoly granted by the patent and would tend to lower prices for the consuming public.

Finally, it is argued that the patent system, rather than a policy of trade secrecy, should be relied upon to protect investments in pharmaceutical research and, therefore, the FDA should not interfere with that system by superimposing on it elements of trade secrecy. While both patent and trade secret law are designed to protect intellectual property, one commentator has pointed out the advantages of the patent system. Basically, patents allow for a far more efficient distribution of scarce research resources. Because patents may be filed in the early stages of research, the patent system puts all other researchers on notice that another party has appropriated the area. Therefore, it is highly unlikely that several firms will carry out substantially the same research and spend tens of millions of dollars, only to discover that the same data has recently been submitted to the FDA by another company. Without the protection given by early patents, drug research would be even more costly and the return on investment even more uncertain than it is today.

The patent system is also a much more reliable source of protection. A trade secret is only protected so long as it remains a secret, yet

202. See Kitch, supra note 20.

203. Id. 278.
secrecy is often quite difficult to maintain. There is, of course, the risk of a leak, but other problems are also present. A research institution may find it necessary to contract with outsiders for financing or complementary technology, but such contracting poses a dilemma. "Disclosure of the secret imperils its value, yet the outsider cannot negotiate until he knows what the secret is." Under the patent system this problem does not arise. It is not necessary to hoard information. Since research is spread out through early patents, there is incentive for firms engaged in research to explore new areas rather than duplicate the work of others.

C. The Arguments Against the Proposals.

The problem with the proposed disclosure procedure is that it does not alleviate and, in fact, is likely to aggravate two of the major problems facing the American pharmaceutical community—the low return on research investment and drug lag.

The two studies sponsored by the FDA on the impact of data disclosure clearly indicate that the proposed policy will result in the loss of tens of millions of dollars each year in new drug research. This loss will occur because release of the data will allow American non-research-intensive firms and foreign firms to market drugs that will divert sales from domestic research-intensive firms. Even though these firms could not market "follower" drugs in the United States (because of the five-year ban on use of the data by competitors in petitions before the FDA and because of the patent protection that most new drugs have in this country), in those countries where drugs are not patentable or are given only minimal patent protection and where data from foreign studies is acceptable in applications to market new drugs, sales that would otherwise go to the original developer of the drug are subject to appropriation by other firms. The vulnerability of new drugs to competition created by the disclosure policy is obviously greatest in those countries that require the submission of data but accept foreign data and do not provide full patent protection for new drugs. This is the case, for example, in Canada, the Netherlands, Swe-

204. Id.
205. See text accompanying notes 178-88 supra.
206. Because research output is concentrated in the large, research-initiative firms, and because the amount of money devoted to research and development varies in direct proportion to retail sales, a loss of retail sales by the large, research-initiative firms will mean that fewer resources will be invested in research and development of new drugs. See text accompanying notes 178-84 supra.
207. See note 36 supra.
208. See Dworkin, Attachment B.
den and Switzerland. In other countries, such as West Germany, where there is some patent protection available, and in nations such as Spain, where the data requirement is not strict (so that the unavailability of the data might not be a barrier to entry), disclosure of data will have some, but less detrimental, impact.

The Dworkin study, conducted at the FDA, attempted to quantify the loss of investment in American pharmaceutical research and development solely on the basis of the loss of sales of research-intensive companies. Sales can be lost to American non-research-intensive firms, in which case the loss to American research is equal to approximately 5% of the shifted retail sales. Sales may also be lost to foreign competitors, in which case the loss to American research is the full amount the research-intensive firm would have committed to research and development, about 10% of the shifted retail sales. Dworkin found that research-intensive firms control approximately 89% of domestic sales and non-research-intensive firms acquire an 11% share of the market for the new drug when the patent expires. Dworkin concludes that research-intensive firms will lose about $51 million a year from the shift in domestic sales alone. In view of the fact that non-research-intensive firms devote a lower percentage of their retail sales to research and development, this will result in a decrease of approximately $2.8 million in research and development.

This is, however, only the tip of the iceberg. The major loss in research funds will come from a loss in foreign sales by American research-intensive firms. By studying the level of patent protection available for new drugs, the need for safety and effectiveness data to enter foreign markets, and the acceptability of foreign data in the nine leading foreign markets for new drugs, Dworkin calculated that one-third of all new drug sales by American firms, or 11% of their total global sales, are vulnerable to "follower" or generic competition. Since American firms control about 25% of world sales, Dworkin assumed that foreign firms would take 75% of the sales of vulnerable drugs. Thus, it was calculated that $599 million per year in foreign market new drug sales would shift to foreign firms. Non-research-intensive American firms would also be able to enter those foreign markets. As-

---

209. Id. 3.
210. Id.
211. Id.
212. Id. 15-18. See text accompanying notes 180-83 supra.
216. Dworkin 15.
suming that they usurp 11% of the remaining sales by American firms in foreign markets, research-intensive firms will lose an additional $20 million annually in new drug sales.\textsuperscript{217} The loss in resources available for all American pharmaceutical research as the result of the sales lost to foreign companies is approximately $53.7 million a year;\textsuperscript{218} research-intensive firms would lose $50.1 million in research funds while non-research-intensive firms would lose the remaining $3.6 million.\textsuperscript{219} The total projected loss to research efforts by American pharmaceutical companies, which account for the vast majority of pharmaceutical discoveries, is thus $56.5 million a year, about 4.7% of total research and development in 1976.\textsuperscript{220} The five-year ban on use of the data in the United States would only affect about $2 million of that loss.\textsuperscript{221}

The validity of the Dworkin study is not above suspicion. Some of the assumptions that were necessary in order to estimate the impact of the disclosure policy merit further inquiry. Dr. Dworkin assumes, for example, that American prescription sales are an accurate sample from which to predict the nature of world sales. Since American sales are equally divided between new drugs\textsuperscript{222} and old drugs, she assumes that world sales are also equally divided. It is necessary to estimate the percentage of drug sales that involve new drugs because the available statistics deal only with total sales. However, it is not clear whether the demand for drugs in this country adequately reflects the nature of drugs sold overseas. Dworkin also assumes stability in the market shares controlled by research-intensive, non-research-intensive and foreign firms without showing any historical evidence in support of this assumption of stability. If the market share controlled by foreign companies has actually increased in recent years and there is reason to suspect a continuing trend, her estimates of the research loss may, in fact, be conservative. However, sensitivity analyses indicate that varying the assumptions regarding market shares does not change the order of magnitude of that estimate.\textsuperscript{223} Finally, the Dworkin study does not reveal the extent to which foreign firms invest in new drug research. The more they invest, the less the decrease in resources available for American pharmaceutical research constitutes an absolute decrease in drug

\textsuperscript{217} Id.
\textsuperscript{218} Id. 17.
\textsuperscript{219} Id.
\textsuperscript{220} Id.
\textsuperscript{221} Id. See text accompanying note 213 supra.
\textsuperscript{222} Dworkin defines a new drug as a single chemical entity or synthesis introduced in the United States for the first time. Other products are combination drugs, duplicate products (generics) and new dosage forms. Dworkin 4.
\textsuperscript{223} Id. 17, Attachment C.
research. Nevertheless, the Dworkin study is extremely helpful in attempting to quantify the impact of disclosure of safety and effectiveness data on research investment.

The other major problem that disclosure of safety and effectiveness data might aggravate is the drug lag. American firms will find it economically beneficial to market their new drugs overseas before making them available in this country. If they were to market first in this country, the data would be released, and all firms would be able to attack their sales in vulnerable markets. By marketing overseas first, American companies can obtain patents in those countries where they are available and attempt to establish a predominant market position in the others. Thus, they can recover a substantial portion of their investment and begin to earn a profit before their sales become vulnerable. The longer they can delay marketing their drugs in this country, the more profitable the new drug might be. The incentive could very well be to withhold drugs from the American market for as long as is politically and economically feasible.

This tendency will be strengthened to the extent that drug companies are wary of public unwillingness to accept the particular risks inherent in a new drug. Although the general public might very well be willing to accept certain risks, industry fears assaults on the drug’s safety by the “Ralph Naders” of the drug world. To combat this, firms will be tempted to market their new drugs abroad for a sufficient period of time to accumulate additional evidence of the drug’s safety and effectiveness. This will be especially true for new drugs produced by foreign companies. These firms are not accustomed to testing their drugs as extensively as American firms because most countries do not require such elaborate testing. When faced with the obligation of making their data public if they market in the United States, many foreign firms may decide to keep their drugs out of this country. Thus, release of safety and effectiveness data could aggravate the drug lag by providing American firms with incentives to market abroad first and by inhibiting the introduction of new drugs in the country by foreign companies.


The primary goals of those seeking disclosure of safety and effectiveness data—opening up FDA decision making and reducing wasteful duplicative testing—are important. However, the costs that would be incurred by releasing the data under the proposed legislation are unacceptable. Thus, it is necessary to focus on how the goals of disclo-

224. See text accompanying notes 200-01 supra.
A three-step system of disclosure is proposed that might serve to fill this need. First, the FDA should release detailed summaries of safety and effectiveness data (analogous to the first report to be disclosed under the proposed legislation\textsuperscript{225}) shortly before the agency intends to hold hearings on the drug's safety and effectiveness. These reports should be made available to anyone, including competitors. If the FDA is seeking a meaningful contribution to the debate over whether to allow marketing of a new drug, it should not exclude evidence that could be submitted by parties having the greatest expertise in new drug research. Competitors, by their very nature, are likely to supply the most critical evaluations of another firm's experiments. If the summaries are to be made available to competitors, however, it is important that these reports not be released prematurely. Disclosure approximately one month prior to the safety and effectiveness hearing should be sufficient.

Second, the data would be \textit{absolutely} protected from disclosure for a specified period of time (for example, five years) after approval of the new drug to allow the developer of the drug to reap a reasonable return on its investment.\textsuperscript{226} After that period of complete protection, a request for more or all of the data should be treated as a request for information falling under exemption 4 of the FOIA. It would, therefore, be within the discretion of the FDA to release the data. In order to do so, however, the agency would be required to show that the benefits of release of that particular data to that particular requester outweigh the likely harm to the original submitter.\textsuperscript{227} If disclosure would cause substantial harm to the competitive position of the original submitter, it would be very difficult for the FDA to justify release.\textsuperscript{228} However, the possibility that the data could be released might speed up therapeutic advances. If another company were on the verge of developing a breakthrough drug and that development could be advanced by the availability of safety and effectiveness data for a previously approved drug, the FDA would have the authority to release that data, except where release would cause substantial harm to the competitive position of the first drug. It may be that such a case will arise only once every ten or twenty years. But to deny the FDA the authority to speed up

\begin{itemize}
\item[225.] See text accompanying notes 191-93 \textit{supra}.
\item[226.] Under current procedure, the safety and effectiveness data in applications that are rejected or withdrawn is available. 21 C.F.R. § 314.14(f) (1978). \textit{See Interim Report} 13-14. See text accompanying note 38 \textit{supra}.
\item[227.] See text accompanying notes 105-06 \textit{supra}.
\item[228.] \textit{See National Parks & Conservation Ass'n v. Morton}, 498 F.2d 765, 770 (D.C. Cir. 1974).
\end{itemize}
therapeutic advances in such a case seems inhumane.

This possibility of disclosure also creates an incentive for the original submitter of the data to seek improvements in its drug. If the drug is patented and the data is absolutely protected, the company holding the patent would not appear to have any reason to improve upon the drug. Since it has a patent for that compound, and most likely for related ones as well, it has no reason to invest in therapeutic improvements that would be covered by the patent. The possibility of disclosure of the data could provide the incentive necessary to encourage that company to explore for improvements.

Finally, after the patent life of a new drug has expired, the FDA should not require other companies independently to develop the same type of safety and effectiveness data. Such a requirement merely serves to protect the original drug from competition by creating an additional barrier to entry and requiring expensive and scientifically unnecessary duplicative testing. This could be prevented either by releasing all of the data after the patent life or by not requiring data from those companies seeking to market exact duplicates of previously approved drugs. The latter alternative is the more desirable. The FDA has already accepted that concept for drugs developed before 1962. Rather than requiring a full NDA with all supporting test data, a firm seeking to market a duplicate of a pre-1962 drug would, under proposed regulations, only have to show the identity of the compounds in an “Abbreviated NDA” (ANDA). The agency is already considering expanding this procedure to cover post-1962 drugs, and it should do so promptly. Such a policy would encourage generic competition and eliminate the need for wasteful duplicative testing. Since the patenting of drugs should be encouraged, it would not be sound policy to afford the data of unpatented drugs greater protection than that given to patented drugs. Thus, it is suggested that ten years after approval of an unpatented drug, its safety and effectiveness data should be released.

It is suggested that this three-part scheme for disclosure of safety and effectiveness data satisfies, to a large extent, the goals of those who seek full release, while minimizing the adverse impact on return on investment in new drug research and the drug lag. This process will open up FDA decision making by allowing access to detailed summaries of safety and effectiveness data shortly before the safety and effectiveness hearing. All of the data, including the protocols, is given absolute protection for five years. This procedure for discretionary re-

229. See text accompanying notes 19-20 supra.
231. See text accompanying notes 202-04 supra.
lease after that time could encourage development of therapeutic advances and thus lower the cost of new drug research. Expanding the use of ANDAs in conjunction with this disclosure policy should facilitate market entry for generic products and thus stimulate competition. Finally, this scheme gives an appropriate level of protection to the data of unpatented drugs. There is no reason to suspect that the proposed scheme would cause research-intensive companies to lose a substantial number of sales during the first years of a new drug’s marketing when its profits must be protected. The combination of patents and the proposed disclosure policy should ensure an adequate return on new drug investment. Furthermore, given the absolute ban on disclosure for five years and the high level of proof necessary for release during the following years, it is unlikely that this policy would exacerbate the drug lag.

V. CONCLUSION

This Comment has surveyed both the legal and policy issues concerning FDA release of safety and effectiveness data. Despite the agency’s insistence that it is unable to release the data, it appears that if the FDA properly promulgated disclosure regulations, such disclosure might be uphold. A change in the FDA’s treatment of this data is a major policy issue that is currently being addressed by Congress in pending legislation. It appears, however, that the disclosure rules contained in the proposed legislation would have the unacceptable effect of decreasing research and development expenditures and aggravating the drug lag. The Comment has presented an alternative disclosure scheme that should fulfill the goals of those seeking full disclosure—opening up FDA decision making and reducing wasteful duplicative testing—without those costs.

Robert M. Halperin